International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.8098359
Original Article
Comparison of PSI and CURB-65 Scores in Predicting Mortality of Hospitalised Patients with Community Acquired Pneumonia
 ,
 ,
 ,
Published
June 30, 2023
Abstract

Background: Community-acquired pneumonia (CAP) is associated with significant morbidity and mortality. Accurate prediction of mortality is crucial for guiding clinical decisions and optimizing patient outcomes. The Pneumonia Severity Index (PSI) and CURB-65 scores are commonly used scoring systems for mortality prediction in CAP. This study aimed to compare the predictive accuracy of the PSI and CURB-65 scores in hospitalised patients with CAP.

Methods: A prospective observational study was conducted in the General Medicine Department of a tertiary care hospital. A total of 100 patients diagnosed with CAP were included. Demographic and clinical data were collected upon admission, and the PSI and CURB-65 scores were calculated. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive accuracy of both scores.

Results: The in-hospital mortality rate was 23% for patients with CAP. The PSI score exhibited an area under the ROC curve of 0.88, indicating a high level of accuracy in predicting mortality. The CURB-65 score demonstrated an AUC of 0.81, suggesting moderate accuracy. Comparison with existing literature showed consistent findings regarding the PSI score's superior performance.

Conclusion: Both the PSI and CURB-65 scores have value in predicting mortality in hospitalised patients with CAP. However, the PSI score demonstrated slightly higher discriminatory power. These scoring systems, along with clinical judgment and additional diagnostic tests, can aid in risk stratification and guide decision-making. Further multicenter studies with larger sample sizes are needed to validate these findings and explore other scoring systems for improved risk stratification in CAP.

Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
2636 Views
442 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved